CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for DelMar Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

DelMar Pharmaceuticals Inc
12707 High Bluff Drive, Suite 200
Phone: (604) 202-1384p:604 202-1384 SAN DIEGO, CA  92130  United States Ticker: DMPIDMPI

Business Summary
DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company focused on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). VAL-083 is being evaluated in a Phase II clinical trial for the treatment of GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. AL-083 is a first-in-class, small-molecule, a deoxyribonucleic acid (DNA) targeting chemotherapeutic. VAL-083 has accessed over 40 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI).
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20206/30/2019YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Robert E.Hoffman 54 6/2/2018 6/2/2018
President, Chief Executive Officer, Director SaiidZarrabian 66 5/21/2018 7/7/2017
Chief Financial Officer ScottPraill 53 1/29/2013 1/29/2013
5 additional Officers and Directors records available in full report.

Business Names
Business Name
0959454 B.C. Ltd.
0959456 B.C. Ltd.
Del Mar Pharma
Del Mar Pharmaceuticals (BC) Ltd.
DMPI
DMPID

General Information
Number of Employees: 4 (As of 6/30/2018)
Outstanding Shares: 11,457,928 (As of 6/30/2020)
Shareholders: 233
Stock Exchange: NASD
Federal Tax Id: 990360497
Fax Number: (604) 202-1384


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, July 06, 2020